Fas (APO-1/CD95)-mediated apoptosis is independent of bcl-2: A study with cell lines overexpressing bcl-2 and with bcl-2 transfected cell lines

International Journal of Oncology

Volumn 12, Issue 1, 1998, Pages 211-220

  Gazitt, Yair ^a   Hu, Wei Xin ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Apoptosis; bcl 2; Fas; Myeloma; Transfection

Indexed keywords

CD19 ANTIGEN; CD38 ANTIGEN; CD40 ANTIGEN; CD45 ANTIGEN; DEXAMETHASONE; FAS ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INTERLEUKIN 6; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA; LIPOCORTIN 5;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CROSS LINKING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; CELL CULTURE; DRUG RESISTANCE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC TRANSFECTION; GENETICS; METABOLISM; MULTIPLE MYELOMA; PATHOLOGY; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ANNEXIN A5; ANTIGENS, CD95; APOPTOSIS; BLOTTING, WESTERN; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENES, P53; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-6; MULTIPLE MYELOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0031974831     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.1.211     Document Type: Article

References (43)

1. Nagata S: Apoptosis mediated by the Fas system. Prog Mol Subcell Biol 16: 87-103, 1996.
2. Suda T, Takahashi T, Golstein P and Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75: 1169-1178, 1993.
3. Yoshino T, Kondo E, Cao L, Takahashi K, Hayashi K, Nomura S and Akagi T: Inverse expression of bcl-2 protein and Fas antigen in lymphoblasts, in peripheral lymph nodes, and activated peripheral blood T and B-lymphocytes. Blood 83: 1856-1861, 1994.
4. Chiu VK, Walsh CM, Liu CC, Reed JC and Clark WR: Bcl-2 blocks degranulation but not Fas-based cell-mediated cytotoxicity. J Immunol 154: 2023-2032, 1995.
5. Nagafuji K, Shibuya T, Harada M, Mizuno S, Takenaka K, Miyamoto T, Okamura T, Gondo H and Niho Y: Functional expression of Fas antigen (CD95) on hematopoietic progenitor cells. Blood 86: 883-889, 1995.
6. + human bone marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 85: 3183-3190, 1995.
7. Barcena A, Park SW, Banapour B, Munench MO and Mechetner E: Expression of Fas/CD95 by primitive hematopoietic progenitors freshly isolated from human fetal liver. Blood 88: 2013-2025, 1996.
8. Druilhe A, Cai Z, Haile S, Chouaib S and Pretolani M: Fas mediated apoptosis in cultured human cosinophils. Blood 87: 2822-2830, 1996.
9. Oyaizu N, McClosky TW, Than S, Hu R, Kalyanaraman VS and Phwa S: Cross-linking of CD4 molecules upregulates Fas antigen expression in lymphocytes by inducing interferon-gamma and tumor necrosis factor-alpha secretion. Blood 84: 2622-2631, 1994.
10. Cleveland JL and Ihle JN: Contenders in Fas/TNF death signaling. Cell 81: 479-482, 1995.
11. Hasegawa J, Kamada S, Kamiike W, Shimizu S, Imazu T, Matsuda M and Tsujimoto Y: Involvement of CPP32/Yama-like proteases in Fas-mediated apoptosis. Cancer Res 56: 1713-1718, 1996.
12. Takayama S, Cazals-Hatem DL, Kitada S, Tanaka S, Miashita T, Hovey RL, Huen D, Rickinson A, Veerapandian P, Krajewski S, Saito K and Reed JC: Evolutionary conservation of function among mammalian, avian, and viral homologs of the bcl-2 oncoprotein. DNA Cell Biol 13: 679-692, 1994.
13. Krajevski S, Tanaka S, Takayama S, Schibler MJ, Fenton W and Reed JC: Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membrane. Cancer Res 53: 4701-4714, 1993.
14. Korsmeyer SJ: Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 80: 879-886, 1992.
15. Reed JC, Kitada S and Miyashita T: Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol 5: S61-S65, 1994.
16. Miyashita T and Reed JC: Bcl-2 oncoprotein blocks chemotherapy induced apoptosis in human leukemia cell line. Blood 81: 151-157, 1993.
17. Reed JC: Bcl-2 and programmed cell death. J Biol Chem 124: 1-6, 1994.
18. Sentman CL, Shutter JR, Hokenbery D, Kanagawa O and Korsmeyer SJ: Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 67: 879-888, 1991.
19. Iwai K, Miawaki T, Takizawa T, Konno A, Ohta K, Yachie A, Seki H and Taniguchi N: Differential expression of bcl-2 and susceptibility to anti-Fas-induced cell death in peripheral blood lymphocytes, monocytes and neutrophils. Blood 84: 1201-1208, 1994.
20. Debatin K-M and Krammer PH: Resistance to APO-1 (CD95)-induced apoptosis in T-ALL is determined by a bcl-2 independent anti-apoptotic program. Leukemia 9: 815-820, 1995.
21. Tian E and Gazitt Y: The role of P53, bcl-2 and box in dexamethasone induced apoptosis in multiple myeloma cell lines. Int J Oncol 8: 719-726, 1996.
22. Hu W-X and Gazitt Y: Bcl-2 plays a major role in resistance to dexamethasone induced apoptosis in multiple myeloma cell lines. Int J Oncol 9: 375-381, 1996.
23. Tian E, Hu W-X and Gazitt Y: Bcl-2 plays a critical role in growth and in spontaneous or induced apoptosis in multiple myeloma cell lines: a study with inducible bcl-2 transfection construct. Int J Oncol 9: 165-169, 1996.
24. Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H and Epstien J: Interleukin-6 prevents dexamethasone induced myeloma cell death. Blood 84: 3063-3070, 1994.
25. Gazitt Y and Erdos GW: Fluctuation and ultrastructural localization of oncogenes and cell cycle regulatory proteins during growth and apoptosis of AGF cells. Cancer Res 54: 950-956, 1994.
26. Martin SJ, Reutelingsperger CPM, McGahon AJ, Rader JA, van Schie RCAA, La Face DM and Green DR: Early distribution of plasma membrane phosphatidyl serine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of bcl-2 and abl. J Exp Med 182: 1545-1556, 1995.
27. + cells do not contain myeloma cells. Blood 86: 381-389, 1995.
28. Alnemri ES, Fernandez TF, Haldar S, Croce CM and Litwak G: Involvement of bcl-2 in glucocorticoid-induced apoptosis in human pre-B leukemia. Cancer Res 52:491-495, 1992.
29. Huang DCS, Cory S and Strasser A: Bcl-2, bcl-Xl and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death. Oncogene 14: 405-414, 1997.
30. Kondo E, Yoshino T, Yamadori I, Matsuo Y, Kawasaki N, Minowada J and Akagi T: Expression of bcl-2 protein and Fas antigen in non-Hodgkin's lymphoma. Am J Pathol 145: 330-336, 1994.
31. Munker R, Lubbert M, Yonehara S, Tuchnitz A, Mertelsmann R and Wilmanns W: Expression of the Fas antigen on primary human leukemia cells. Ann Hematol 70: 15-17, 1995.
32. Robertson MJ, Manley TJ, Pichert G, Cameron C, Cochran KJ, Levine H and Ritz J: Functional consequences of APO-I/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells. Leuk Lymphoma 17: 51-61, 1995.
33. Weller M, Malipiero U, Aguzzi A, Reed JC and Fontana A: Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 95: 2633-2643, 1995.
34. Itoh N, Tsujimoto Y and Nagata S: Effect of bcl-2 on Fas antigen-mediated cell death. J Immunol 151: 621-627, 1993.
35. Shima Y, Nishimoto N, Ogata A, Fujii Y, Yoshizaki K and Kishimoto T: Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood 85: 757-764, 1995.
36. Hata H, Matsuzaki H, Takeya M, Yoshida M, Sonoki T, Nagasaki A, Kuribayashi N, Kawano F and Takatsuki K: Expression of Fas/APO-1 (CD95) and apoptosis in tumor cells from patients with plasma cell disorders. Blood 86: 1939-1945, 1995.
37. Westendorf JJ, Lammert JM and Jelinek DF: Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines. Blood 85: 3566-3576, 1995.
38. Harada H, Kawano MM, Huang M, Harada Y, Iwato K, Tanabe O, Tanaka H, Sakai H and Kuramoto A: Phenotypic differentiation of plasma cells from mature myeloma cells. Blood 81: 2658-2663, 1993.
39. Schattner EJ, Elkon KB, Yoo D-H, Tumang J, Krammer PH, Crow MK and Friedman SM: CD40 ligation induce APO-1/Fas expression on human B-lymphocytes and facilitates apoptosis through the APO-1/Fas pathway. J Exp Med 182: 1557-1565, 1995.
40. + T-cell induction of Fas-mediated apoptosis in Burkitt's lymphoma. Blood 88: 1375-1382, 1996.
41. Urashima M, Chauhan D, Uchiyama H, Freeman GJ and Anderson KC: CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood 85: 1903-1912, 1995.
42. Westendorf JJ, Ahmann GJ, Armitage RJ, Spriggs MK, Lust JA, Greipp PR, Katzmann JA and Jelinek DF: CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL-6 secretion by human myeloma cell line. J Immunol 152: 117-128, 1994.
43. Chauhan D, Kharbanda S, Ogata A, Urashima M, Teoh G, Robertson M, Kufe DW and Anderson KC: Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood 89: 227-234, 1997.